CONTEXT: A subset of patients diagnosed with idiopathic hypogonadotropic hypogonadism (IHH) later achieves activation of their hypothalamic-pituitary-gonadal axis with normalization of steroidogenesis and/or gametogenesis, a phenomenon termed reversal. OBJECTIVE: The objective of this study was to determine the natural history of reversal and to identify associated phenotypes and genotypes. DESIGN, SETTING, AND SUBJECTS: This was a retrospective review of clinical, biochemical, and genetic features of patients with IHH evaluated at an academic medical center. MAIN OUTCOME MEASURES: History of spontaneous fertility, regular menses, testicular growth, or normalization of serum sex steroids, LH secretory profiles, brain imaging findings, and sequences of 14 genes associated with IHH were reviewed. RESULTS: Of 308 patients with IHH, 44 underwent reversal. Time-to-event analysis estimated a lifetime incidence of reversal of 22%. There were no differences in the rates of cryptorchidism, micropenis, or partial pubertal development in patients with reversal vs IHH patients without reversal. Fifteen patients with reversal (30%) had Kallmann syndrome (IHH and anosmia); one had undetectable olfactory bulbs on a brain magnetic resonance imaging scan. Subjects with reversal were enriched for mutations affecting neurokinin B signaling compared with a cohort of IHH patients without reversal (10% vs 3%, P = .044), had comparable frequencies of mutations in FGFR1, PROKR2, and GNRHR, and had no mutations in KAL1. Five men did not sustain their reversal and again developed hypogonadotropism. CONCLUSIONS: Reversal of IHH may be more widespread than previously appreciated and occurs across a broad range of genotypes and phenotypes. Enrichment for mutations that disrupt neurokinin B signaling in patients who reversed indicates that, despite the importance of this signaling pathway for normal pubertal timing, its function is dispensable later in life. The occurrence of reversal in a patient with no olfactory bulbs demonstrates that these structures are not essential for normal reproductive function. Patients with IHH require lifelong monitoring for reversal and, if reversal occurs, subsequent relapse also may occur.
CONTEXT: A subset of patients diagnosed with idiopathic hypogonadotropic hypogonadism (IHH) later achieves activation of their hypothalamic-pituitary-gonadal axis with normalization of steroidogenesis and/or gametogenesis, a phenomenon termed reversal. OBJECTIVE: The objective of this study was to determine the natural history of reversal and to identify associated phenotypes and genotypes. DESIGN, SETTING, AND SUBJECTS: This was a retrospective review of clinical, biochemical, and genetic features of patients with IHH evaluated at an academic medical center. MAIN OUTCOME MEASURES: History of spontaneous fertility, regular menses, testicular growth, or normalization of serum sex steroids, LH secretory profiles, brain imaging findings, and sequences of 14 genes associated with IHH were reviewed. RESULTS: Of 308 patients with IHH, 44 underwent reversal. Time-to-event analysis estimated a lifetime incidence of reversal of 22%. There were no differences in the rates of cryptorchidism, micropenis, or partial pubertal development in patients with reversal vs IHH patients without reversal. Fifteen patients with reversal (30%) had Kallmann syndrome (IHH and anosmia); one had undetectable olfactory bulbs on a brain magnetic resonance imaging scan. Subjects with reversal were enriched for mutations affecting neurokinin B signaling compared with a cohort of IHH patients without reversal (10% vs 3%, P = .044), had comparable frequencies of mutations in FGFR1, PROKR2, and GNRHR, and had no mutations in KAL1. Five men did not sustain their reversal and again developed hypogonadotropism. CONCLUSIONS: Reversal of IHH may be more widespread than previously appreciated and occurs across a broad range of genotypes and phenotypes. Enrichment for mutations that disrupt neurokinin B signaling in patients who reversed indicates that, despite the importance of this signaling pathway for normal pubertal timing, its function is dispensable later in life. The occurrence of reversal in a patient with no olfactory bulbs demonstrates that these structures are not essential for normal reproductive function. Patients with IHH require lifelong monitoring for reversal and, if reversal occurs, subsequent relapse also may occur.
Authors: Hilana M Lewkowitz-Shpuntoff; Virginia A Hughes; Lacey Plummer; Margaret G Au; Richard L Doty; Stephanie B Seminara; Yee-Ming Chan; Nelly Pitteloud; William F Crowley; Ravikumar Balasubramanian Journal: J Clin Endocrinol Metab Date: 2011-11-09 Impact factor: 5.958
Authors: Nelly Pitteloud; James S Acierno; Astrid U Meysing; Andrew A Dwyer; Frances J Hayes; William F Crowley Journal: J Clin Endocrinol Metab Date: 2004-12-21 Impact factor: 5.958
Authors: Janne Tornberg; Gerasimos P Sykiotis; Kimberly Keefe; Lacey Plummer; Xuan Hoang; Janet E Hall; Richard Quinton; Stephanie B Seminara; Virginia Hughes; Guy Van Vliet; Stan Van Uum; William F Crowley; Hiroko Habuchi; Koji Kimata; Nelly Pitteloud; Hannes E Bülow Journal: Proc Natl Acad Sci U S A Date: 2011-06-23 Impact factor: 11.205
Authors: Nelly Pitteloud; Frances J Hayes; Paul A Boepple; Suzzunne DeCruz; Stephanie B Seminara; David T MacLaughlin; William F Crowley Journal: J Clin Endocrinol Metab Date: 2002-01 Impact factor: 5.958
Authors: Margaret F Lippincott; Silvia León; Yee-Ming Chan; Chrysanthi Fergani; Rajae Talbi; I Sadaf Farooqi; Christopher M Jones; Wiebke Arlt; Susan E Stewart; Trevor R Cole; Ei Terasawa; Janet E Hall; Natalie D Shaw; Victor M Navarro; Stephanie Beth Seminara Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Maryse Ahow; Le Min; Macarena Pampillo; Connor Nash; Junping Wen; Kathleen Soltis; Rona S Carroll; Christine A Glidewell-Kenney; Pamela L Mellon; Moshmi Bhattacharya; Stuart A Tobet; Ursula B Kaiser; Andy V Babwah Journal: Endocrinology Date: 2014-08-22 Impact factor: 4.736
Authors: Chrysanthi Fergani; Leanne Mazzella; Lique M Coolen; Richard B McCosh; Steven L Hardy; Nora Newcomb; Pasha Grachev; Michael N Lehman; Robert L Goodman Journal: Endocrinology Date: 2016-10-05 Impact factor: 4.736
Authors: Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi Journal: Nat Rev Dis Primers Date: 2019-05-30 Impact factor: 52.329
Authors: Aniruthan Renukanthan; Richard Quinton; Benjamin Turner; Peter MacCallum; Leighton Seal; Andrew Davies; Richard Green; Jane Evanson; Márta Korbonits Journal: Endocrine Date: 2015-03-05 Impact factor: 3.633
Authors: Ravikumar Balasubramanian; Sheena Chew; Sarah E MacKinnon; Peter B Kang; Caroline Andrews; Wai-Man Chan; Elizabeth C Engle Journal: J Clin Endocrinol Metab Date: 2015-01-05 Impact factor: 5.958
Authors: Ihsan Turan; B Ian Hutchins; Bulent Hacihamdioglu; L Damla Kotan; Fatih Gurbuz; Ayca Ulubay; Eda Mengen; Bilgin Yuksel; Susan Wray; A Kemal Topaloglu Journal: J Clin Endocrinol Metab Date: 2017-06-01 Impact factor: 5.958
Authors: Daiane Beneduzzi; Ericka B Trarbach; Le Min; Alexander A L Jorge; Heraldo M Garmes; Alessandra Covallero Renk; Marta Fichna; Piotr Fichna; Karina A Arantes; Elaine M F Costa; Anna Zhang; Oluwaseun Adeola; Junping Wen; Rona S Carroll; Berenice B Mendonça; Ursula B Kaiser; Ana Claudia Latronico; Letícia F G Silveira Journal: Fertil Steril Date: 2014-07-10 Impact factor: 7.329